Predictive Oncology’s Breakthrough in Drug Repurposing Offers Hope for Patients
/in Drug repurposing, Preclinical Research/by MaxPhase 1 Soon Recruiting: MK-2400 (Ifinatamab Deruxtecan) for Metastatic Prostate Cancer
/in Clinical Trial, Metastatic, Phase 1/by MaxNewsletter 15/2025
/in Newsletter/by MaxLAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Hi fellow warriors! This week brings a solid batch of seven articles. From bold new strategies to cutting-edge trials, it seems that momentum is building. Stay strong and fight on! As usual, we also have a podcast if you prefer to listen […]
Phase 1 Trial: The COSMYC Trial, ZEN-3694 Combination With BAT
/in Clinical Trial, Metastatic, Phase 2/by MaxPhase 2 Trial Enrolling: Combination Therapy for Metastatic Castration-Resistant Prostate Cancer
/in Clinical Trial, Metastatic, Phase 2/by MaxPhase 1 Enrolling: Sylvester Cancer Center Launches Innovative Clinical Trial for High-Grade Neuroendocrine Tumors
/in Clinical Trial, Metastatic, Phase 1/by MaxAdvancements in Delivery: Gene Therapy Could Help Prostate Cancer Treatment
/in CRISPR, Delivery, Preclinical Research/by MaxUpdate: FC705 Signals a Leap Forward in Prostate Cancer Therapy, Outperforming Pluvicto
/in Clinical Trial, Metastatic, Phase 2/by MaxNew Molecule Boosts Vaccine Power Against Cancer and Viruses, In Vivo Study
/in Immunotherapy, Preclinical Research/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 225Ac abiraterone abiraterone acetate ADC ADT AI ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T clinical trial crispr darolutamide docetaxel drug repurposing drug resistance enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data T-cell therapy
Latest Posts
- ASTX295 + Olaparib: A Targeted Strategy for BRCA2‑Mutant, TP53‑Wild‑Type Cancers March 25, 2026
- How exercise protects the prostate: a new CNTF pathway that calms tumor‑supporting cells and boosts immune attack March 25, 2026
- MUC1‑C Targeting with XYA02‑8‑ADC, for Castration‑Resistant and Neuroendocrine Prostate Cancer March 25, 2026
- JZY‑2233: A PSMA‑Targeted Degrader‑Antibody Conjugate for Advanced Prostate Cancer March 25, 2026